Boehringer Ingelheim and Lilly will present the latest data from their diabetes portfolio at the 71st American Diabetes Association (ADA) Scientific Sessions in San Diego on June 25-29. Study results evaluating the investigational dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin tablets, as well as the investigational sodium glucose cotransporter−2 (SGLT−2) inhibitor BI-10773 will be featured in 27 presentations.
Two pieces of linagliptin data were selected by ADA as President's posters, a prestigious session showcasing 100 specially-selected posters on Sunday, June 26 and repeated on Monday, June 27. An additional two linagliptin studies evaluating cardiovascular safety will be highlighted as late-breakers.
Among the 27 presentations are the following:
Linagliptin data
BI-10773 data
Health Economics and Outcomes Research Data
Study highlights nutrition therapy's potential to manage gestational diabetes effectively